WORLDWIDE CONTACT US ABOUT US INVENTING FOR LIFE PRODUCTS RESEARCH LICENSING NEWSROOM CAREERS INVESTORS An estimated 2.7-3.9 million Americans are living with chronic hepatitis C virus (HCV) infection, a disease that can lead to long-term health consequences like liver failure or liver cancer. For more than 30 years, Merck has been at the forefront of the response to chronic HCV and our team continues to work tirelessly to advance scientific knowledge of this significant global public health issue. IN THE PAST DECADE, MERCK'S CLINICAL DEVELOPMENT PROGRAMS IN CHRONIC HCV INFECTION HAVE: ENROLLED APPROXIMATELY 10,000 PARTICIPANTS INCLUDED MORE THAN 135 CLINICAL TRIALS IN APPROXIMATELY 40 COUNTRIES MERCK IS PROUD OF ITS CONTRIBUTIONS TOWARD ADVANCING THE SCIENCE OF CHRONIC HCV Our pursuit of innovation will continue. As part of our longstanding leadership in infectious diseases, Merck is committed to broadening access to help make treatment an option for all patients infected with HCV. We will continue our collaborations with the scientific community, patient advocates, local governments and other stakeholders to accelerate our collective goal of addressing the burden of chronic HCV. Learn more about Hepatitis C: A Silent Disease and Growing Concern VIEW FACT SHEET Published April 2018 Copyright. © 2009-2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Forward-Looking Statement Privacy Terms of Use Site Map